ELI LILLY AND COMPANY Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
ELI LILLY AND COMPANY (LLY) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of -$121.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2026-02-12
- ELI LILLY AND COMPANY effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2025 was -$121.00M.
- ELI LILLY AND COMPANY effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2010 was $0.00, a 100.00% decline from fiscal 2009.
- ELI LILLY AND COMPANY effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2009 was $600.00K, a 99.83% decline from fiscal 2008.
- ELI LILLY AND COMPANY effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2008 was $359.30M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|
| 2025-12-31 | -$121.00M 10-K · filed 2026-02-12 |
| 2010-12-31 | $0.00 10-K · filed 2011-02-22 |
| 2009-12-31 | $600.00K 10-K · filed 2011-02-22 |
| 2008-12-31 | $359.30M 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |